Spots Global Cancer Trial Database for breast adenocarcinoma
Every month we try and update this database with for breast adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | NCT02453620 | Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Invasive Breast... Malignant Solid... | Biopsy Blood Sample Bone Scan Computed Tomogr... Entinostat Ipilimumab Nivolumab Pharmacogenomic... Pharmacological... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | NCT02453620 | Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Invasive Breast... Malignant Solid... | Biopsy Blood Sample Bone Scan Computed Tomogr... Entinostat Ipilimumab Nivolumab Pharmacogenomic... Pharmacological... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy | NCT06401889 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Estrogen Recept... Progesterone Re... | Non-Interventio... | 18 Years - | Mayo Clinic | |
| Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients | NCT04300829 | Breast Adenocar... Radiation Derma... Radiation Toxic... | cicaderma + sim... Simple hygiene ... | 18 Years - | Centre Leon Berard | |
| Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy | NCT06401889 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Estrogen Recept... Progesterone Re... | Non-Interventio... | 18 Years - | Mayo Clinic | |
| Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | NCT05183828 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Invasive Breast... | Biospecimen Col... Letrozole Questionnaire A... | 18 Years - | University of Washington | |
| Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | NCT03106415 | Breast Adenocar... Metastatic Trip... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Binimetinib Laboratory Biom... Pembrolizumab | 18 Years - | Mayo Clinic | |
| Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer | NCT03137693 | Breast Cancer Breast Cancer F... Breast Adenocar... | Standard of Car... Breast-conservi... | 50 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | NCT02824575 | Breast Cancer Breast Adenocar... Human Epidermal... Recurrent Breas... Stage IV Breast... | Rebastinib Paclitaxel Eribulin Mesyla... | 18 Years - | Montefiore Medical Center | |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | NCT00005970 | Breast Adenocar... HER2 Positive B... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... | Aromatase Inhib... Cyclophosphamid... Doxorubicin Hyd... Laboratory Biom... Paclitaxel Tamoxifen Citra... Trastuzumab | 18 Years - | National Cancer Institute (NCI) | |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | NCT02824575 | Breast Cancer Breast Adenocar... Human Epidermal... Recurrent Breas... Stage IV Breast... | Rebastinib Paclitaxel Eribulin Mesyla... | 18 Years - | Montefiore Medical Center | |
| Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer | NCT04517838 | Breast Adenocar... HER2-Positive B... | Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas | NCT01942629 | Lung Adenocarci... Breast Adenocar... Pancreatic Duct... | their will be n... | 18 Years - 75 Years | Rambam Health Care Campus | |
| Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | NCT02530489 | Breast Adenocar... Invasive Breast... Triple-Negative... | Atezolizumab Nab-paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas | NCT01942629 | Lung Adenocarci... Breast Adenocar... Pancreatic Duct... | their will be n... | 18 Years - 75 Years | Rambam Health Care Campus | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients | NCT04300829 | Breast Adenocar... Radiation Derma... Radiation Toxic... | cicaderma + sim... Simple hygiene ... | 18 Years - | Centre Leon Berard | |
| Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer | NCT04517838 | Breast Adenocar... HER2-Positive B... | Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | NCT00310180 | Breast Adenocar... Hormone Recepto... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIB Brea... | Anastrozole Exemestane Laboratory Biom... Letrozole Quality-of-Life... Radiation Thera... Tamoxifen Citra... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
| Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | NCT03250676 | Breast Neoplasm... Breast Cancer Estrogen-recept... Cancer, Breast Breast Cancer F... Breast Adenocar... Estrogen Recept... ER Positive | H3B-6545 | 18 Years - | Eisai Inc. | |
| Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer | NCT04857697 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Stage I Lung Ca... Stage II Lung C... Stage III Lung ... | Biopsy Biospecimen Col... Probiotic Therapeutic Con... | 18 Years - | Mayo Clinic | |
| RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | NCT04139993 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Breast Adenocar... Invasive Breast... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Triple-Negative... | Microbiota-base... | 18 Years - | Mayo Clinic | |
| CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | NCT04891718 | Solid Tumour | MVC-101 Nivolumab MVC-101 + Nivol... | 18 Years - | Presage Biosciences | |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | NCT00310180 | Breast Adenocar... Hormone Recepto... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIB Brea... | Anastrozole Exemestane Laboratory Biom... Letrozole Quality-of-Life... Radiation Thera... Tamoxifen Citra... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas | NCT01942629 | Lung Adenocarci... Breast Adenocar... Pancreatic Duct... | their will be n... | 18 Years - 75 Years | Rambam Health Care Campus | |
| Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | NCT03106415 | Breast Adenocar... Metastatic Trip... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Binimetinib Laboratory Biom... Pembrolizumab | 18 Years - | Mayo Clinic | |
| Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer | NCT03137693 | Breast Cancer Breast Cancer F... Breast Adenocar... | Standard of Car... Breast-conservi... | 50 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study | NCT06234488 | Breast Cancer Breast Neoplasm... Breast Adenocar... Breast Cancer S... Breast Cancer S... Breast Cancer I... Breast Cancer i... | 18 Years - | Medical College of Wisconsin | ||
| Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | NCT02530489 | Breast Adenocar... Invasive Breast... Triple-Negative... | Atezolizumab Nab-paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer | NCT04517838 | Breast Adenocar... HER2-Positive B... | Biospecimen Col... | 18 Years - | Mayo Clinic | |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | NCT00433511 | Breast Adenocar... | Bevacizumab Cyclophosphamid... Doxorubicin Hyd... Laboratory Biom... Paclitaxel Placebo Adminis... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | NCT01730833 | HER2-positive B... Recurrent Breas... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Breast Adenocar... Inflammatory Br... | pertuzumab trastuzumab paclitaxel albu... laboratory biom... | 19 Years - | City of Hope Medical Center | |
| Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | NCT02530489 | Breast Adenocar... Invasive Breast... Triple-Negative... | Atezolizumab Nab-paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | NCT01245712 | Breast Adenocar... Ductal Breast C... Invasive Breast... Stage 0 Breast ... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... | Accelerated Par... Proton Beam Rad... Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
